Live Breaking News & Updates on Ascendi oncology program update

Stay updated with breaking news from Ascendi oncology program update. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates

31.05.2023 - – TransCon IL-2 β/γ in Phase 1 clinical trial showed monotherapy clinical activity in heavily pre-treated cancer patients with clear dose dependent response on cytotoxic immune cells – TransCon IL-2 β/γ administered every 3 weeks was . Seite 1 ....

Copenhagen , Køavn , Denmark , Ascendis-pharma , Jan-mikkelsen , Stina-singel , Webcast-of-ascendi-oncology-program , Company-oncology , Head-of-clinical-development , Ascendi-oncology-program-update , Executive-vice-president , Clinical-development